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Introduction
Patient reported outcomes (PROs), including quality of life 
(QoL), are becoming recognized as important elements in 
providing evidence for medical product labeling (Food and 
Drug Administration, 2009; Patrick et al., 2007). Although 
some researchers have advocated for keeping PRO analysis 
simple (Cox et al., 1992), it is not clear how this can be 
accomplished when data are missing, as PRO data often are, 
because they are often suspected of missing non-randomly 
(D. F. Fairclough, 2010). Many applied researchers use sub-
standard approaches; two reviews on the handling of missing 
data in randomized controlled trials (RCTs) showed that 
most RCTs have missing PRO data and have used problem-
atic approaches (Fielding, Maclennan, Cook, & Ramsay, 
2008; Wood, White, & Thompson, 2004), which can result in 
bias and/or inefficiency (M. L. Bell & Fairclough, 2013; 
Carpenter & Kenward, 2008; D. F. Fairclough, 2010).
Missing Data
Missing data can cause biased estimates of treatment effect 
and change over time, particularly if patients with missing 
data have poorer health than those whose data are complete. 
R. J. A. Little and Rubin (1987) defined three types of miss-
ingness. When the probability of missingness is unrelated to 
the patient’s PROs or other covariates, data are missing com-
pletely at random (MCAR). When the probability of miss-
ingness depends only on observed PRO data and (possibly) 
other explanatory factors, data are missing at random (MAR). 
Data missing not at random (MNAR) are those where miss-
ingness depends on the value of the missing data itself, even 
when taking observed data into account.
Summary Measures and Statistics
Summary measures (or individual’s raw data summaries) are 
an approach to simplifying longitudinal data by reducing an 
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A common approach to the analysis of longitudinal patient reported outcomes (PROs) is the use of summary measures such 
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individual’s data to a single value, such as the maximum, the 
slope over time, or the area under the curve (AUC). Groups 
can then be compared using a t test or similar. Although the 
simplicity of summary measures is appealing, an obvious 
problem is how to determine the value of the summary mea-
sure for individuals when some of their data are missing.
Summary statistics (or parameter estimate summaries) 
reduce values to a single estimate from the parameters of a 
model. In contrast to summary measures, summary statistics 
summarize group values not individuals. An important fea-
ture is that there is no need to specify decision rules regard-
ing missing data, as is required for summary measures 
(discussed further below).
This article focuses on AUC as a summary. Although 
AUC is commonly used in pharmacokinetic analysis to esti-
mate total drug exposure, by estimating the area under the 
concentration time curve, we consider AUC in the context of 
PRO assessment.
Literature
AUC has been used to evaluate QoL in cancer RCTs, for 
example (Neoptolemos et al., 2004; Vasey et al., 2004). Both 
of these highly cited papers used individual summary mea-
sures, but neither explained how they handled missing data 
in their computations.
AUC has not been investigated using simulated data 
informed by PRO questionnaires, although some have con-
sidered single PRO data sets (Curran et al., 2000; D. L. 
Fairclough, 1997; Qian et al., 2000). R. J. Little and 
Raghunathan (1999) investigated using individuals’ slopes 
over time as summary measures with various estimation 
techniques and missing data types. They found when data 
were not MCAR, slopes were biased compared with maxi-
mum likelihood estimation. Dawson (1994) used simulation 
to investigate various summary measures including AUC but 
did not compare the commonly used “naïve” summary mea-
sures approach with summary statistics. Both Little and 
Dawson simulated data with normal distributions, whereas 
the distribution of PRO data is generally truncated due to the 
bounded nature of PRO scales.
Aim
Our aim was to use simulation to compare the bias of sum-
mary measures versus summary statistics for PRO data 
examining sensitivity to the
1. method of calculating the summary measures in the 
presence of dropout;
2. missing data mechanism and allocation between 
groups;
3. pattern of change (trajectory).
We demonstrate these methods on data from an RCT for 
patients with renal carcinoma.
Motivating Examples
Our research was informed and motivated by two studies. 
The first was an observational study and was used to identify 
typical covariance in our simulations. The second was a ran-
domized Phase III trial that illustrates the motivation for con-
sidering AUC as a summary, as well as the challenges in 
implementing the analyses.
Study 1: The Australian Ovarian Cancer Study is a popu-
lation based study that recruited women aged 18 to 79 
years with ovarian cancer from hospitals and registries 
(Price et al., 2013). The QoL sub-study of 798 women 
collected various PROs, at up to 8 time points, including 
QoL as measured by the Functional Assessment of 
Cancer-General (FACT-G) (Cella et al., 1993). The 
FACT-G contains 27 items covering aspects of physical, 
social, family, emotional, and functional well-being. The 
items are summed and scaled to a range of 0 to 100, where 
a higher score reflects better QoL.
Study 2: The second study is a multicenter randomized 
Phase III trial comparing two treatments in advanced 
renal cell carcinoma patients (D. F. Fairclough, 2010). In 
all, 197 patients had QoL assessed at four time points: 
baseline, 2, 8, and 17 weeks. By the fourth assessment, 
only 43% of the surviving patients had complete QoL 
data, which was 35% of all patients.
The objective was to compare overall QoL between the 
two treatment groups, thus the choice of AUC is appropriate. 
The non-linear nature of the trajectories over time (see Figure 
1) particularly motivates this, as testing at any specific time 
point may underestimate or overestimate the treatment dif-
ferences. Using a summary also avoids problems with multi-
plicity that would occur by comparing groups at each time 
point. The main PRO in this trial was the Trial Outcome 
Index: a sum of the FACT-G physical and functional well-
being scores and 17 disease specific items. It has been scaled 
to a range of 0 to 100, with higher values indicating better 
QoL. QoL trajectories over time, stratified by dropout time 
and treatment, are shown in Figure 1. Because the within-
arm trajectories differ substantially by attrition group, these 
data are unlikely to be MCAR.
AUC: Summary Measures and 
Summary Statistics
Summary Measures for an Individual
The AUC summary measure, approximated with the trape-
zoid method, is calculated for the ith subject as
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where Y
ij
 is the observed PRO for the ith subject at the jth 
time, j = 1, . . ., m, and Y
ij
 
− 1
 is the j − 1th time for the ith 
subject. This is simply the area of each trapezoid formed by 
connecting consecutive Y values and is a weighted linear 
combination of individual measurements with the average 
PRO level of each pair of adjacent assessments weighted by 
the duration of the time period between those two assess-
ments, summed over m − 1 time periods. Because groups can 
be compared using the difference in mean AUC with a t test 
(or similar, including linear regression if covariates are to be 
included), the advantage of this approach is its simplicity. 
The assumptions are also simple: When the sample size is 
large enough, AUC and the difference in AUC are approxi-
mately normally distributed, even when they are made up of 
non-normal observations. A clear disadvantage to this 
approach is that there is no unified principle for handling 
missing data.
Various ad hoc approaches for handling missing data have 
been used with summary measures. These include complete 
case analysis, where patients who drop out are excluded 
(e.g., Cheng et al., 2010; Ishihara, 1999); last observation 
carried forward (LOCF; Akhtar-Danesh, 2001) where miss-
ing data are replaced with the last observed value; mean 
imputation (Carusone, Goldsmith, Smieja, & Loeb, 2006) 
where an individual’s missing data are replaced with the 
mean of their observed data; extrapolation (Carusone et al., 
2006); and interpolation (Qian et al., 2000). The latter four 
approaches are forms of simple imputation and are prone to 
inflating the Type I error rate due to variance underestima-
tion and overstatement of the sample size (see Chapter 8 in 
D. F. Fairclough, 2010).
Summary Statistics for Groups
Summary statistics for computing AUC are obtained post 
estimation from the parameter estimates of a multivariate 
model, often a mixed model. For the kth group, the equation 
is
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k j j
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m kj kj
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where µˆkj is the kth group’s expected value of Y at time j and 
is estimated using a linear combination of the parameter esti-
mates after a model has been fit. This could be accomplished 
by using an estimate statement in SAS, or a lincom statement 
Figure 1. QoL in the renal cell carcinoma trial, stratified by dropout time and treatment group.
Note. Treat = 0 indicates control therapy, treat = 1 indicates experimental therapy. The possible range of QoL is 0 to 100, with higher values indicating 
better QoL. QoL = quality of life.
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in Stata, which would also be used to estimate differences in 
AUC. If there are no missing data, and a saturated mixed 
model (see below) unadjusted for covariates (beyond time 
and group assignment) is used, the AUC estimated in this 
way is the same as the mean of the individual AUCs. With 
summary statistics, the modeling deals with missing data 
(see below).
Mixed Models
Mixed models comprise a flexible family of regression mod-
els that allows for non-independent data, like in longitudinal 
studies (Fitzmaurice, Laird, & Ware, 2011). When time is 
included as a categorical factor, so that the mean at each time 
is computed, they are sometimes referred to as means mod-
els, response profile analyses, saturated models, or repeated-
measures mixed models (D. F. Fairclough, 2010; Fitzmaurice 
et al., 2011; Mallinckrodt, Clark, Carroll, & Molenberghs, 
2003). When time is included as a continuous variable, these 
models have been referred to as linear mixed models or 
growth curve models. Estimation is performed by maximum 
likelihood, or more often, restricted maximum likelihood. 
Observed data lend information about missing data and give 
mixed models the appealing feature that missing data, as 
long as it is MCAR or MAR, do not result in biased esti-
mates, if the model is correctly specified (D. F. Fairclough, 
2010; Fitzmaurice et al., 2011). If data are MAR, missing-
ness depends on observed data and covariates, so omission 
of an important covariate or some of the observed data would 
be an incorrect specification of the model.
PRO Trajectories and Summaries
Summaries have been used to aid in interpretation as well as 
reducing the number of statistical tests and the subsequent 
increased likelihood of Type I errors (D. F. Fairclough, 
2010). Matthews, Altman, Campbell, and Royston (1990) 
and D. F. Fairclough (2010) have discussed various outcome 
trajectories, summaries, and potential hypotheses that may 
be appropriate for them. For example, if the PRO is changing 
in a way that is known to be relatively constant over time, the 
best summary might be the slope. If the treatment effect is 
transient, and the question of interest is whether there is a 
difference at a specific time point or whether there is a differ-
ence in worst symptoms experienced, then the minimum or 
maximum might be the most appropriate summary. Sustained 
effects over time might best be assessed by AUC or the mean 
over time (these are similar when times between assessments 
are equal; Curran et al., 2000).
Simulation Study
We address the aims of our study by varying the trajectories, 
as well as the type and rates of missing data as shown in 
Table 1. Each of the methods for imputing missing values for 
the calculation of the summary measures is a common 
approach in applied research, as described earlier. Sample 
size, covariance parameters, and baseline values were held 
constant and informed by QoL data from Study 1.
Underlying Model
We simulated data for a randomized, two group, longitudinal 
design of five time points, using a repeated-measures (means) 
mixed model:
Y t t t t t
t t
ij i
i
= + + + + +
× + × +
β β β β β β
β β
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where Y
ij
 is the outcome for the ith subject at the jth time i = 
1, . . ., n = 200, j = 1, . . ., m = 5, t1 is an indicator variable 
for time 1 (t2 for time 2, etc., with subscripts suppressed as 
common times are used for all subjects), group
i
 = 0 (control), 
1 (treatment), b
i
 ~ N(0, σb
2 ) represents between-person 
effects, σb
2
 = between-person variance, e
ij
 ~ N(0, σe2 ) repre-
sents within-person effects, and σe2  = within-person vari-
ance. The error terms were independent. Based on the ovarian 
cancer data, we set the mean baseline (for both groups) to 77, 
σb
2  = 150, σe2  = 60 and within-person correlation over time 
0.7. Beta values varied by trajectory, and are given in Table 1.
Table 1. Simulation Set-Up. 100,000 Samples of Each Combination of Data Pattern, Missingness, and Missingness Allocation Were 
Simulated.
Data pattern/PRO trajectorya Missingness
Missingness allocation between 
groups Analysis
Summary measures missing data 
approaches
1. Linear decline
β = (77, 75, 73, 71, 69, 77, 76.5, 76, 75.5, 75)
2. Plateau
β = (77, 73, 69, 69, 69, 77, 76.5, 76, 75.5, 75)
3. Temporary change
β = (77, 70, 76, 76, 76, 77, 76, 75, 75.5, 76)
1. Complete
2. MCAR
3. MAR
4. MNAR
1. Equal (30% in each group)
2.  Unequal (20% in treatment, 30% 
in control)
1. Mixed model summary statistic
2. Individual summary measures
1. Complete case analysis
2. Extrapolation
3. M imputation
4. LOCF
Note. PRO = Patient reported outcomes; MCAR = missing completely at random; MAR = missing at random; MNAR = missing not at random; LOCF = last observation carried 
forward.
aβ refers to the vector of coefficients in Equation 1.
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To mimic ceiling effects commonly found in PRO data, 
we used a truncated normal distribution. Truncation was 
achieved by conditioning within the program to re-draw if 
any Y
ij
 were less than 0 or greater than 100, conditional on 
the random effect b
i
. This approach resulted in a smooth dis-
tribution, rather than creating spikes at 0 or 100, that occurred 
when a simple substitution rule was used. We simulated 
100,000 samples for each of three patterns of change over 
time, selected to illustrate a range of plausible patterns of 
QoL in cancer clinical trials (Figure 2), informed by discus-
sion with biostatisticians and researchers in the field.
Missing Data Patterns
For each of the three data patterns, we simulated data that 
were complete, MCAR, MAR, and MNAR. The effect of 
treatment on missingness was considered by using equal 
drop-out rates between the two groups, at approximately 
30%; and unequal dropout rates between groups, with 20% 
missing in the treatment group and 30% missing in the con-
trol group. Missing data were created as follows. For each 
subject i, and at each time j > 1, the probability that y
ij
 was set 
to missing, P(M
ij
 = 1), was a function of that subject’s previ-
ous value, y
ij
 
− 1
, to create MAR data. The subject’s current 
value, y
ij
, was conditioned on to create data that were MNAR. 
Specifically, for MAR, P M eij j( ) ( )
-= = +1 1 1 θ , where 
θ j ij j j jy y p p= - - log( - )1 1 1 , and y j-1  = the mean of y at the 
j − 1th time point. The value p
j
 varied depending on the tra-
jectory and on whether missingness was allocated equally or 
unequally, for example, using equal missingness between 
groups and the linear decline, the vector p = .05, .07, .09, .12. 
MCAR missing data were created by random deletion. To 
make the missing data as realistic as possible, we increased 
the proportion of missingness with each time point. Only 
monotone (dropout) missing patterns were simulated.
As a sensitivity analysis, a threshold missingness mecha-
nism was also used: for MAR, if yij − 1 < threshold, then delete 
y
ij
 with a given probability; for MNAR, if yij < threshold, 
then delete y
ij
 with a given probability. Details are given in 
the appendix.
Calculation of Summary Measures
The summary measure AUC was calculated from the raw 
data, with each patient’s five PRO measurements summa-
rized into one value. We handled missing data in the follow-
ing ways: (a) complete case analysis only, (b) linear 
extrapolation by individual using the previous two observa-
tions (requiring at least two observations), (c) imputation 
using the mean of the individuals’ previously observed data, 
and (d) LOCF.
Analysis Approaches
In each data set, the difference in AUC between the groups 
was estimated using a t test for summary measures and a 
mixed model and contrast for the summary statistic AUC. 
The t test tested the null hypothesis H0 : µAUC0 = µAUC1, where 
µAUC1 is estimated by AUC AUC0 = ∑ =1 1n ii
n , for example, 
for the control group. The mixed model included time as a 
categorical variable, group, and the interaction of time by 
group, as well as a random intercept (a means model). Using 
the model in Equation 1, the estimated mean at any time j = 1, 
. . ., m = 5 is µ β β  j j j m= + ×+ group , where group = 0,1; the 
difference in means between groups is β j m+ ; and the differ 
ence in AUC is AUC AUC +2 +2 +2 +6 7 8 9 101 0 1 2
      - ( ).= β β β β β
Percent bias for the test of difference between groups was 
computed by 100 × (estimate − true value) / true value, so 
that positive values indicate overestimates and negative 
Figure 2. Simulated QoL data patterns over time.
Note. Solid line represents Group 0 (control), dashed line represents Group 1 (treatment). QoL = quality of life.
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values represent underestimates. We also present the bias 
divided by the estimated standard error (SE) that represents 
how far off the t statistic for the test of difference in AUC is 
from the t statistic computed from a non-biased estimate. A 
small value, say less than 0.1, is unlikely to change conclu-
sions. Precision of estimates of difference in AUC are given 
by the width of the 95% confidence interval (CI) width. All 
simulations and analyses were performed in SAS v9.2.
Simulation Results
Missingness rates for the simulated data are shown in Table 
2, for the MAR case. Rates at each time point for the MCAR 
and MNAR data were similar and are not shown. The differ-
ence in AUC between groups was normally distributed, 
despite having come from a truncated normal distribution. 
This is to be expected based on the central limit theorem but 
is mentioned to underscore the validity of parametric 
approaches.
The main results from the simulations are shown in Table 
3. When no data were missing, there was no bias for the AUC 
estimated from the parameters of a mixed model (summary 
statistic) or the AUC computed from individual summary 
measures.
The mixed model estimates showed negligible bias for 
both MCAR and MAR data: less than 1% for all patterns and 
drop-out rates. When the data were MNAR, the bias of the 
mixed model estimates was low for most scenarios, except 
for the temporary change, unequal drop-out case, which had 
a 29% underestimation.
Bias for all the individual AUC approaches (complete 
case and simple imputation) was larger, ranging from 27% 
underestimation to 67% overestimation, and varied 
according to the imputation method and data pattern. 
Complete case analyses yielded unbiased results for MCAR 
data, as expected. For MAR and MNAR data, the bias ranged 
from −29% to −6%. Simple imputation methods yielded bias 
for all scenarios, even in the MCAR case. For example, bias 
with LOCF ranged from −24% to 8% for MCAR data, and 
−24% to 16% for the MAR case.
Precision, as measured by the 95% CI widths was compa-
rable for all patterns, although the mixed models had slightly 
smaller CI widths and the complete case analysis consis-
tently had the largest CI widths, due to smaller sample size. 
The results using the threshold drop-out mechanism (the sen-
sitivity analysis) showed very similar patterns (see the 
appendix).
Renal Carcinoma Example
Summary measures using the various simple imputation 
techniques and summary statistics computed from a mixed 
model as described above were computed. The results are 
shown in Figure 3 and Table 4. The most dramatic and not 
unexpected result occurs with the complete case analysis, 
with an estimated treatment difference of 0.56 as compared 
with the mixed model estimate of −20.8. This illustrates the 
impact of selection bias; when analysis is limited to those 
patients who stay on trial (most of whom remained progres-
sion free) and assume that missingness is completely unre-
lated to the outcome, we see no differences across treatment. 
In contrast, when we implement methods that attempt to 
address missing data, we identify a difference between the 
treatment arms. The simple imputation methods all gave 
similar results (about −16, favoring the control arm). 
Assuming that the data are MAR and the model was 
Table 2. Percentage of MARa Missing Data at Each Time Point by Data Pattern and Group.
Time
Allocation of 
missingness Data pattern % missing 1 2 3 4 5
Equal Linear decline Control 0 6 13 21 31
Treatment 0 6 13 21 30
Plateau Control 0 5 13 22 31
Treatment 0 5 12 20 28
Temporary change Control 0 5 13 21 30
Treatment 0 5 12 20 29
Unequal Linear decline Control 0 6 13 22 31
Treatment 0 4 9 14 20
Plateau Control 0 5 12 21 31
Treatment 0 4  9 14 20
Temporary change Control 0 5 13 21 29
Treatment 0 4  8 14 20
Note. The target rates of missingness at the final time point were 30% for both groups in equal and 30% versus 20% for unequal allocation. MAR = missing 
at random; MNAR = missing not at random.
aValues for MNAR data were similar and are not shown.
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Table 3. Comparison of Individual Summary Measures With Mixed Model Summary Statistics: Estimated Difference in AUC (Treat − 
Control), Percent Bias, and Precisiona for 100,000 Samples of n = 200 Subjects.
Equal missingness Unequal missingness
Data pattern and missingness
AUC approach and imputation 
method 95% CI width Estimate Percent bias Bias/SE Estimate Percent bias Bias/SE
Linear decline
 No missing data Individual AUC 26.3 11.14 0 0 11.14 0 0
 Mixed model AUC 26.3 11.14 0 0 11.14 0 0
 MCAR Individual AUC  
  1. Complete caseb 31.6 11.15 0.1 0 11.15 0.1 0
  2. Extrapolation 29.3 11.12 −0.2 0 11.10 −0.3 0
  3. M imputation 26.7 9.44 −15.2 −0.25 9.21 −17.4 −0.28
  4. LOCF 27.3 8.64 −22.4 −0.36 8.48 −23.9 −0.38
 Mixed model AUC 26.7 11.14 0 −0.01 11.14 0 0
 MAR Individual AUC  
  1. Complete caseb 30.5 10.53 −5.6 −0.08 9.37 −15.8 −0.24
  2. Extrapolation 29.8 11.20 0.5 0.01 11.28 1.4 0.02
  3. M imputation 26.6 9.27 −16.8 −0.28 9.18 −17.5 −0.29
  4. LOCF 27.4 8.52 −23.6 −0.38 8.51 −23.5 −0.38
 Mixed model AUC 26.7 10.8 −0.6 −0.01 11.05 −0.7 −0.01
 MNAR Individual AUC  
  1. Complete case 30.4 10.23 −8.3 −0.11 9.08 −18.4 −0.27
  2. Extrapolation 29.3 10.97 −1.6 −0.02 10.62 −4.5 −0.07
  3. M imputation 26.4 9.12 −18.1 −0.30 8.82 −20.7 −0.34
  4. LOCF 27.1 8.41 −24.6 −0.40 8.16 −26.7 −0.43
 Mixed model AUC 26.5 10.96 −1.7 −0.03 10.73 −3.6 −0.06
Plateau
 No missing data Individual AUC 26.5 18.66 0 0 18.66 0 0
 Mixed model AUC 26.5 18.66 0 0 18.66 0 0
 MCAR Individual AUC  
  1. Complete caseb 31.9 18.65 0 0 18.65 0 0
  2. Extrapolation 29.6 19.85 0 0.16 19.85 6.4 0.16
  3. M imputation 26.9 16.53 −11.4 −0.31 16.30 −12.7 0.34
  4. LOCF 27.6 17.71 −5.1 −0.13 17.56 −5.9 −0.15
 Mixed model AUC 26.5 18.66 0 0 18.66 0 0
 MAR Individual AUC  
  1. Complete case 30.5 17.50 −6.2 −0.15 16.58 −11.3 −0.28
  2. Extrapolation 30.2 20.25 8.5 0.21 20.48 9.5 0.23
  3. M imputation 26.7 16.31 −12.6 −0.34 16.35 −12.5 −0.34
  4. LOCF 27.5 17.62 −5.6 −0.15 17.75 −8.1 −0.13
 Mixed model AUC 26.8 18.58 −0.4 −0.01 18.61 −0.5 −0.01
 MNAR Individual AUC  
  1. Complete case 30.7 17.23 −7.7 −0.18 16.27 −13.0 −0.32
  2. Extrapolation 29.7 19.74 5.8 0.14 19.60 4.9 0.12
  3. M imputation 26.5 15.91 −14.7 −0.40 15.83 −15.0 −0.42
  4. LOCF 27.3 17.21 −7.8 −0.21 17.18 −5.1 −0.22
 Mixed model AUC 26.6 18.36 −1.6 −0.04 18.23 −0.7 −0.07
Temporary change
 No missing data Individual AUC 26.2 4.23 0 0 4.25 0 0
 Mixed model AUC 26.1 4.23 0 0 4.25 0 0
 MCAR Individual AUC 26.1 4.23 0 0  
  1. Complete caseb 31.4 4.26 0.6 0 4.26 0.2 0
  2. Extrapolation 29.7 5.76 36.1 0.2 5.97 40.5 0.2
  3. M imputation 26.6 4.87 15.2 0.01 4.67 10.0 0.06
  4. LOCF 27.3 4.58 7.5 0.05 4.39 3.3 0.02
 Mixed model AUC 26.5 4.23 0 0 4.25 0 0
 MAR Individual AUC  
  1. Complete case 30.0 3.94 −6.8 −0.04 3.00 −29.3 −0.17
  2. Extrapolation 30.8 6.73 59.0 0.31 7.10 66.9 0.36
  3. M imputation 26.7 4.96 17.3 0.11 4.97 16.8 0.11
  4. LOCF 27.6 4.82 14.0 0.08 4.92 15.7 0.10
 Mixed model AUC 26.5 4.25 0.5 0 4.27 0.3 0.002
 MNAR Individual AUC  
  1. Complete case 30.0 3.97 −6.1 −0.03 3.02 −29.0 −0.17
  2. Extrapolation 29.8 5.81 37.4 0.20 5.55 30.5 0.17
  3. M imputation 26.4 4.74 12.1 0.08 4.60 8.2 0.05
  4. LOCF 27.2 4.50 6.3 0.04 4.35 2.2 0.01
 Mixed model AUC 30.0 3.94 −6.8 −0.04 3.00 −29.3 −0.17
Note. Results for precision were similar for the case of equal and unequal missing data rates in the two groups so only equal rates’ results are shown. AUC = area under the 
curve; CI = confidence interval; SE = standard error; MCAR = missing completely at random; LOCF = last observation carried forward; MAR = missing at random; MNAR = 
missing not at random.
aPercent bias is 100 × (estimate − true) / true. Width of 95% CI reflects precision.
bOnly patients with complete data were analyzed.
cNegative values indicate underestimation of the difference in AUC between groups.
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specified correctly so that the mixed model estimate is cor-
rect, the estimated bias is about 24%.
With regard to PRO trajectories over time, we note that 
the extrapolation technique appears to stand out in contrast to 
the other methods (Figure 2). This does not imply that this 
technique is consistently problematic but clearly illustrates 
that imputation choices are very trial specific and difficult to 
make a priori.
Discussion
We conducted a simulation study to compare the perfor-
mance of the AUC computed in two ways, as a raw data 
summary measure where each individual’s PRO over time 
reduces to one number that can then be compared between 
groups with a t test; and using summary statistics, in which 
AUC is computed for groups based on estimated parame-
ters from a mixed model. We aimed to examine the bias of 
these two methods and their sensitivity to assumptions 
about missing data and patterns of change. With no missing 
data, the two approaches gave identical results. With any 
type of missing data, summary statistics were consistently 
superior to summary measures, in terms of bias and preci-
sion. The bias resulting from the summary statistic approach 
was very small, even when data were MNAR. The bias 
resulting from the summary measure approach was 
Figure 3. Quality of lifetime trajectories, by treatment group and analytical approach.
Note. LOCF = last observation carried forward.
Table 4. Estimates of Difference in QoL AUC (Treat − Control) for Renal Carcinoma RCT Data.
Approach Analysis Estimate 95% CI p value
Summary Statistics Mixed model −20.8 [−33.6, −7.9] .002
Summary Measures Complete case 0.56 [−17.5, 18.7] .95
Extrapolation −16.3 [−31.8, −0.80] .04
M imputation −15.7 [−26.7, −4.8] .005
 LOCF −16.8 [−28.3, −5.3] .005
Note. QoL = quality of life; AUC = area under the curve; RCT = randomized controlled trial; CI = confidence interval; LOCF = last observation carried 
forward.
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considerable under some conditions, and importantly, the 
size and direction of bias was unpredictable, varying with 
data pattern, missingness, and imputation method. The 
complete case analysis of AUC summary measures consis-
tently had the lowest precision (due to reduced sample 
size), and the bias with this approach doubled when the rate 
of missing data differed between groups. These results were 
consistent when group missing data rates were equal and 
unequal.
Relation to Other Literature
Various statisticians (Carpenter & Kenward, 2008; D. F. 
Fairclough, 2010; Mallinckrodt et al., 2003; Molenberghs 
et al., 2004) have warned about the bias that can occur 
with LOCF. Despite these warnings, LOCF is still often 
used (Fielding et al., 2008; Wood et al., 2004). We found 
that LOCF underestimated the treatment effect by approx-
imately 25% in the linear decline pattern even when data 
were MCAR or MAR. In contrast, for the temporary 
decline pattern, it produced overestimates. This illus-
trates the findings of Molenberghs et al. (2004, p.454) 
who demonstrated algebraically that even when data are 
MCAR, “the bias can be positive or negative and can 
even induce an apparent treatment effect when one does 
not exist.”
Our results confirm Bell, Kenward, Fairclough, and 
Horton (2013) by demonstrating that equal dropout between 
groups does not imply unbiased results; we have shown that 
even if the missingness patterns are similar between the 
groups, the use of individual summary measures can cause 
considerable bias.
Although summary measures are equivalent to sum-
mary statistics (for certain models, such as those shown 
here), when no data are missing, a complete data set in 
longitudinal studies is rare, so missingness must be con-
sidered in any valid analysis. Qian et al. (2000, p.2672) 
stated that they assumed the data were MCAR because the 
patterns of missingness between the treatment groups 
were similar and also because “they wanted to keep the 
analyses manageable and it is not easy to identify the 
missing value processes in practice.” Simplicity is an 
admirable goal, but it should not be used to the detriment 
of the validity of the study. Perhaps researchers use simple 
imputation methods because of a desire to follow the 
intention to treat principle and are not aware that likeli-
hood methods can be consistent with this principle 
(Molenberghs et al., 2004).
When maximum likelihood was used, there was minimal 
bias in the MNAR scenarios. This finding is consistent with 
others (Mallinckrodt et al., 2003; Molenberghs et al., 2004), 
but generalizations should be formed cautiously, as different 
drop-out mechanisms may show a larger influence.
Recommendations
Although maximum likelihood methods including mixed 
models are not simple, there are types that are simpler than 
others, such as the means model with a random intercept in 
the RCT setting, as shown in this article, or the so-called 
mixed effects repeated-measures model (Mallinckrodt et al., 
2003). Both of these models, because they use time categori-
cally, are robust to misspecification of the outcome’s mean 
structure over time. While some have argued that the com-
pound symmetric correlation structure assumed by this 
model is unrealistically simple (Fitzmaurice et al., 2011), 
others have argued that this is a reasonable assumption in the 
context of RCTs (Frison & Pocock, 1992). The correlation 
over time in the PRO data from both examples was well 
approximated with a compound symmetric structure. There 
are trade-offs between complexity and simplicity, but we 
believe that the advantage of having the potential of no bias 
for data that are MAR, and possibly reduced bias for MNAR 
in a range of scenarios, outweighs the benefits of the simplic-
ity of summary measures. Leaders in the missing data field 
have recommended that the MAR assumption is the best 
starting point for analyses (7, 23, 24, 26, 27), and we recom-
mend it for summaries also.
Limitations
There are limitations to our research. We examined a lim-
ited number of missing data scenarios. There are different 
types of missingness mechanisms, that is, methods of creat-
ing missing data that may influence results to a degree; we 
examined two among many possible probabilistic models 
for dropout as a function of the outcome. The data were 
generated using a mixed model, similar to the one used to 
model the data and may contribute to the low level of bias 
using mixed models. We only considered one covariance 
structure (compound symmetry), explored a limited num-
ber of trajectories, and considered only dropout. However, 
in our experience, dropout is a larger problem than inter-
mittent missing data. Multiple imputation was not explored. 
However, if multiple imputation is used but without auxil-
iary data, results will be nearly identical to those from a 
mixed model fitted to the incomplete data set (D. F. 
Fairclough, 2010).
Conclusion
If AUC is used as a longitudinal summary when data are not 
MCAR, it should be estimated using maximum likelihood 
(such as a mixed model) using summary statistics rather than 
from individuals’ summary measures to minimize bias in 
treatment effect estimation. An area of future research is how 
the results presented here could be applied in the field phar-
macokinetic analyses.
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Appendix
1. Sensitivity of results to the method of missing data 
creation.
To ascertain whether the results were influenced by the methods 
of creating missing data, we performed a sensitivity analysis using 
1,000 samples with a different method.
MAR data were created as follows. Let M
ijk
 = 1 if the outcome 
Y
ijk
 is missing for the ith subject at the jth time in the kth group 
(k = 0,1). Then
P M c Y Yijk i j k j k=( ) = × − ( ) − −1 1 1 1Φ σ( ) ( ), , ,
where
c = 0.18 and Φ is the value of the cumulative distribution function 
at Y
i(j − 1)k
 for a normal distribution with mean Yk j( )−1  (the mean for 
the kth group at the time point previous to the jth) and standard devia-
tion σ. For MNAR data, the current value, Y
ijk
 and Yjk  were used.
The results given in Table A1 are nearly identical to the 
original results in the article.
Table A1. Comparison of Individual Summary Measures With Mixed Model Summary Statistics: Estimated Difference in AUC  
(Treat − Control), Percent Bias, and Precisiona for 1,000 Samples of n = 200 subjects.
Data pattern and missingness AUC approach and imputation method 95% CI width Estimate Percent bias
Linear decline
 No missing data Individual AUC 26.3 11.21 0
 Mixed model AUC 26.3 11.21 0
 MAR Individual AUC  
  1. Complete caseb 30.5 10.71 −4. 5
  2. Extrapolation 30.1 11.10 −1.0
  3. M imputation 26.4 9.05 −19.3
  4. LOCF 27.2 8.37 −25.3
 Mixed model AUC 26.8 11.10 −1.4
 MNAR Individual AUC  
  1. Complete case 30.4 10.61 −5.4
  2. Extrapolation 30.0 10.96 −2.2
  3. M imputation 26.5 8.97 −20.0
  4. LOCF 27.2 8.29 −26.1
 Mixed model AUC 26.7 11.01 −1.8
Plateau
 No missing data Individual AUC 26.6 18.78 0
 Mixed model AUC 26.5 18.78 0
 MAR Individual AUC  
  1. Complete case 30.1 17.79 −5.3
  2. Extrapolation 30.8 20.13 7.2
  3. M imputation 26.5 15.56 −17.1
  4. LOCF 27.3 17.98 −10.2
 Mixed model AUC 26.9 18.54 −1.3
 MNAR Individual AUC  
  1. Complete case 31.1 17.98 −4.3
  2. Extrapolation 30.6 20.04 6.7
  3. M imputation 26.7 15.33 −18.4
  4. LOCF 27.4 16.60 −11.6
 Mixed model AUC 26.9 18.53 −1.3
Temporary change
 No missing data Individual AUC 26.2 4.23 0
 Mixed model AUC 26.1 4.23 0
 MAR Individual AUC  
  1. Complete case 30.5 3.86 −8.6
  2. Extrapolation 31.7 7.13 68.6
  3. M imputation 26.6 4.77 12.8
  4. LOCF 27.5 4.80 13.5
 Mixed model AUC 26.7 4.23 0
 MNAR Individual AUC  
  1. Complete case 30.5 4.09 −3.4
  2. Extrapolation 31.1 6.71 58.7
  3. M imputation 26.7 4.62 9.3
  4. LOCF 27.5 4.55 7.6
 Mixed model AUC 26.6 4.24 0.2
Note. AUC = area under the curve; CI = confidence interval; MAR = missing at random; LOCF: last observation carried forward; MNAR = missing not at random.
aPercent bias is 100 × (estimate − true) / true. Negative values indicate underestimation of the difference in AUC between groups. Width of 95% CI reflects precision.
bOnly patients with complete data were analyzed.
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